Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

Table 3 Univariate analyses of overall survival

	Eribulin (n = 91)	Capecitabine (n = 79)
	p	p
HR+	0.013	0.39
ER+	0.13	0.05
PgR+	0.04	0.84
HER2-	0.84	0.89
Surgical history	0.024	0.85
Neoadjuvant/adjuvant chemotherapy	0.63	0.58
Previous hormone therapy	0.01	0.8
Previous anthracycline	0.35	0.09
Previous taxane	0.13	0.28
Albumin ≥4.1 g/dL	0.06	0.12
Age ≥60 years	0.12	0.63
LDH <222 U/L	0.001	0.002
CRP <0.15 mg/dL	0.09	0.019
NLR <3	0.013	0.037
ALC ≥1,500/µL	0.11	0.06
LMR ≥5	0.013	0.014
PLR <250	0.002	0.13

ALC absolute lymphocyte count; CRP C-reactive protein; ER oestrogen receptor; HER2 human epidermal growth factor receptor type 2; HR hormone receptor; LDH lactate dehydrogenase; LMR lymphocyte-to-monocyte ratio; NLR neutrophil-to-lymphocyte ratio; PgR progesterone receptor; PLR platelet-to-lymphocyte ratio

ISSN: 1471-2407